Capricor shares soar as potential FDA lifeline revives Duchenne drug hopes

Capricor Therapeutics shares rose 70% after the FDA agreed to review new 24-month data focused on upper limb muscle function for its Duchenne muscular dystrophy drug, deramiocel, pushing back the decision deadline.

This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.